Angiogenesis in salivary gland tumors: from clinical significance to treatment

Abstract

The available data suggest that microvessel density (MVD) evaluation may be capable of discriminating between benign and malignant SGTs, while the use of CD105 antibody seems to be the most suitable. Substantial evidence also suggests that MVD and VEGF expression could be used as prognostic factors in malignant SGTs. Although several agents have shown antiangiogenic activities in adenoid cystic carcinoma cells and xenograft tumors, limited effectiveness in the existing clinical trials was noted. Further studies are strongly recommended for the validation of already well-known and the identification of novel prognostic and predictive angiogenic markers. There is also a strong demand for relatively larger cohorts, homogenous samples referring to same histological SGT subtypes and including an equivalent number of low- and high-grade SGTs.

Immunoexpression of hoxb7 and hoxb9 in salivary gland tumours

“…CD105 represents a suitable angiogenic marker, because it is preferentially associated with recently formed blood vessels . In the current study, we observed that the great majority of stained vessels were small and thin‐walled structures and the expression of this protein was increased in malignancies than in pleomorphic adenoma.…”

The Impact of Angiogenesis in the Most Common Salivary Gland Malignant Tumors

“…The latest, also known as endoglin, is an activated ECs marker, part of the transforming growth factor β receptor complex that plays a key role in tumor-induced angiogenesis [17]. However, the evaluation of tumor angiogenic activity by MVD assessment lies under the constriction that not all microvessels detected necessarily contribute to tumor perfusion [18].…”

Treatment response to eribulin and anlotinib in lung metastases from rare perianal adenoid cystic carcinoma: a case report

“…Angiogenesis inhibitor is a critical component in ACC treatment [ 6 , 18 ]. The microvessel density and VEGFR expression were closely related to the worse survival of ACC [ 12 ]. Some studies indicated that when combined with eribulin, antiangiogenic therapy could play a stronger antitumor effect [ 26 , 27 ].…”

“…Chemotherapy and targeted therapies have proven poor response rate and survival benefit [ 6 , 10 ]. Recent studies suggest that the microtubule inhibitor eribulin [ 11 ] and antiangiogenic therapy [ 12 , 13 ] could control ACC to some extent. Here, we report the first case of advanced perianal ACC with multiple pulmonary metastases that presented a durable response to eribulin and anlotinib after the failure of conventional radiotherapy and chemotherapy.…”